Oral Micronized Progesterone and Appetite & Cravings Changes

What Is Oral Micronized Progesterone and Why Does It Affect Appetite?

Oral micronized progesterone is bioidentical progesterone suspended in peanut oil, ground to microscopic particles so the gut can absorb it. The body converts a significant fraction to neuroactive metabolites, especially allopregnanolone, within an hour of swallowing a dose. Allopregnanolone is a potent positive allosteric modulator of GABA-A receptors, the same receptors that benzodiazepines and alcohol activate. This central sedative action explains the drowsiness many women notice, and it also connects directly to appetite.

GABA-A activation in the hypothalamus reduces inhibitory tone on neuropeptide Y (NPY) neurons, which are among the brain's most potent appetite-stimulating circuits. Separately, progesterone at physiologic doses has been shown to increase basal metabolic rate slightly while simultaneously driving carbohydrate preference, a combination that can feel confusing: you burn a little more, yet you want more bread.

How This Differs From Synthetic Progestins

Not all progestogens behave alike in the appetite network. Medroxyprogesterone acetate (MPA), the synthetic progestin used in the Women's Health Initiative, binds glucocorticoid receptors at therapeutic doses, promoting cortisol-like fat deposition and hunger signals. OMP does not bind glucocorticoid receptors to any clinically relevant degree. The PEPI Trial (JAMA 1995) showed that women on conjugated equine estrogen plus OMP had significantly better HDL-cholesterol outcomes than those on CEE plus MPA, a proxy for OMP's more favorable metabolic footprint. Still, "better than MPA" does not mean appetite-neutral. OMP's neuroactive metabolite pathway creates its own hunger signal that MPA largely lacks.

The Allopregnanolone Mechanism in Plain Language

Think of allopregnanolone as a volume dial on the brain's calming system. Turn it up acutely and you feel sleepy, relaxed, less anxious. Sustain that elevated volume chronically and your hypothalamus starts reading reduced inhibitory tone as a green light to seek food, especially calorie-dense carbohydrates. This is the same mechanism behind progesterone-driven cravings in the late luteal phase of a natural menstrual cycle, when progesterone peaks between days 19 and 28. OMP essentially recreates that late-luteal hormonal environment every evening.

How Appetite Changes Vary Across Life Stages

Reproductive Years

Women taking OMP for luteal phase support in fertility cycles or for cycle regulation report that the appetite effect layered on top of their already elevated endogenous progesterone can feel magnified. If your natural luteal progesterone already drives carb cravings, adding 200 mg of OMP nightly for the second half of your cycle may intensify those cravings noticeably. Data here are almost entirely observational; no dedicated RCT has tracked caloric intake as a primary endpoint in this population.

Women with PCOS are a specific group to watch. PCOS is associated with baseline hyperinsulinemia and carbohydrate sensitivity, so any agent that amplifies carbohydrate craving sits on top of an already vulnerable metabolic platform. If you have PCOS and are prescribed OMP for cycle regulation or endometrial protection, monitoring dietary carbohydrate intake and fasting glucose in the first three months is reasonable clinical practice.

Perimenopause

This is the stage where the appetite-and-cravings side effect matters most clinically. Perimenopause is characterized by wildly fluctuating estrogen and declining progesterone, a shift that already disrupts sleep, mood, and eating behavior. When OMP is added for endometrial protection or sleep support, the GABA-A effects on appetite layer onto a metabolic environment already tending toward abdominal weight gain.

Perimenopausal women also experience a shift in fat distribution from subcutaneous to visceral, partly driven by declining estradiol. Adding appetite stimulation on top of that shift means the clinical conversation about OMP should include explicit discussion of dietary strategy, not just hormone dosing.

Postmenopause

In postmenopause, OMP is almost always prescribed alongside systemic estrogen for endometrial protection. The standard continuous dose is 100 mg nightly. At this dose, appetite changes tend to be milder than at 200 mg, and most women find that consistent bedtime dosing blunts the effect because they are asleep during the peak allopregnanolone window. Women who take OMP earlier in the evening and stay awake for 2-3 hours post-dose report more pronounced food-seeking behavior in that window.

A 2019 observational cohort published in Menopause journal found that postmenopausal women on combined estradiol plus OMP maintained weight similarly to untreated controls over 12 months, suggesting that at 100 mg, the appetite effect may not translate into meaningful weight gain for most women when diet is otherwise stable.

The Specific Cravings Pattern: What Women Actually Report

Based on the mechanistic literature and clinical reports, OMP-related appetite changes follow a recognizable pattern that differs from general hunger. You can use this framework to distinguish OMP-related cravings from other causes:

OMP-Characteristic Craving Pattern:

1. Timing: Appetite increase occurs 60-120 minutes after the dose, corresponding to peak allopregnanolone levels.
2. Quality: Cravings are specifically for high-carbohydrate, high-fat foods (pasta, bread, crackers, sweets) rather than protein.
3. Duration: Peaks within 2-3 hours and resolves with sleep; not present throughout the next day.
4. Dose-dependence: More pronounced at 200 mg than 100 mg. Dropping from 200 mg to 100 mg in appropriate clinical contexts often reduces the craving intensity by roughly half in patient-reported experience.
5. Tolerance: Some women report that the appetite spike diminishes after 4-8 weeks as the brain partially adapts to the new allopregnanolone baseline.

Non-OMP Causes to Rule Out:

• Insufficient daytime calories (the OMP dose makes a restrictive diet feel unbearable at night)
• Concurrent sleep deprivation, which independently drives ghrelin up and leptin down
• Declining estradiol levels if HRT dose is inadequate, since estrogen suppresses appetite-stimulating signals

Does OMP Cause Weight Gain? What the Evidence Actually Shows

The short answer is: OMP-related weight gain has not been demonstrated in adequately powered trials. The PEPI Trial followed 875 women for 3 years across four hormone regimens and found no significant difference in body weight between OMP-containing and estrogen-only arms. Body weight was not a primary endpoint, and caloric intake was not measured, which are meaningful limitations.

A 2016 meta-analysis in the Cochrane Database examining progestogen type in HRT found insufficient data to draw conclusions about weight outcomes specifically for micronized progesterone versus synthetic progestins. The evidence gap here is real and worth acknowledging plainly: we do not have a high-quality RCT with dietary tracking that answers the weight question for OMP in either perimenopause or postmenopause.

What women do report clinically, and what mechanistic data support, is an increased risk of consuming excess calories in the post-dose window. Whether that translates to weight gain depends heavily on whether that evening eating is offset elsewhere. Women who skip a structured lunch and then encounter an OMP-amplified appetite at 10 PM are more likely to see the scale move than women who eat balanced daytime meals.

Insulin Sensitivity and Carbohydrate Metabolism

Progesterone at supraphysiologic doses has been shown to mildly impair insulin sensitivity in short-term studies, but at standard OMP doses (100-200 mg), the effect appears modest compared to injectable depot MPA. For women with insulin resistance, pre-diabetes, or type 2 diabetes, the combination of mildly impaired insulin signaling and carbohydrate-specific cravings in the evening is still worth monitoring. Checking a fasting glucose and HbA1c at baseline and at 3-6 months after starting OMP is reasonable in higher-risk women.

Managing Appetite and Cravings on OMP: Practical Strategies

Managing appetite side effects starts with timing. Taking OMP at bedtime, defined as within 15 minutes of actually getting into bed, positions the peak allopregnanolone window during sleep so the appetite signal fires while you are unconscious. This single adjustment resolves the evening-craving problem for many women without requiring a dose change.

Dietary Approaches That Work With the Mechanism

• Eat a protein-forward evening meal before your dose. Protein at dinner raises satiety hormones (peptide YY, GLP-1) that partially blunt the carbohydrate-seeking drive during the allopregnanolone peak.
• Do not skip daytime meals to compensate for anticipated evening eating. Arriving at your OMP dose time already calorically depleted dramatically worsens the craving intensity.
• Keep the kitchen closed after the dose. The window of heightened appetite typically lasts 90-150 minutes. If you are asleep within 30 minutes of dosing, this is a non-issue.
• If evening meals still feel poorly controlled, discuss with your clinician whether continuous 100 mg dosing might be appropriate for your situation instead of sequential 200 mg dosing.

When to Ask Your Clinician About a Dose Adjustment

Contact your prescriber if:

• You are gaining weight steadily (more than 2 lbs per month over 3 consecutive months) without a clear dietary explanation.
• Nighttime eating is disrupting sleep or causing GI distress.
• Carbohydrate cravings are present throughout the day, not just post-dose, as that pattern suggests a different cause.
• You have been diagnosed with binge-eating disorder; OMP's appetite-stimulating mechanism can interact with existing binge patterns and warrants specialist co-management.

Pregnancy, Lactation, and Contraception

Pregnancy: OMP (Prometrium) as manufactured contains peanut oil and is FDA-labeled specifically for endometrial protection in postmenopausal women on estrogen. It is also used off-label for luteal phase support in assisted reproduction and to reduce preterm birth risk in women with a short cervix; in those contexts, progesterone is not considered teratogenic and is used intentionally during early pregnancy. However, self-initiating OMP or continuing a perimenopause dose into an unrecognized pregnancy is a different scenario entirely.

If you are perimenopausal and prescribed OMP, pregnancy remains possible until you have had 12 consecutive months of amenorrhea. A pregnancy test before starting OMP and reliable contraception throughout treatment are warranted until menopause is confirmed. ACOG recommends that women who are not clearly postmenopausal use contraception concurrently with hormone therapy.

Lactation: Progesterone is present in breast milk in small amounts. Exogenous OMP increases milk progesterone levels. High progesterone inhibits lactogenesis, so OMP is generally avoided in women who are actively establishing milk supply in the first weeks postpartum. After milk supply is established (usually by 6-8 weeks postpartum), lower-dose progesterone-only options are sometimes used under specialist guidance, but standard 100-200 mg OMP for HRT indications is not routinely used in breastfeeding women. Discuss timing and alternatives with your OB or lactation specialist.

Contraception note for teratogen context: OMP itself is not a recognized teratogen, but confirming the absence of pregnancy before and during use in perimenopausal women is standard practice given the non-zero pregnancy risk in this group.

Who This Is Right For, and Who Should Proceed Carefully

Good Candidates for OMP With Monitoring

• Postmenopausal women on systemic estrogen who need endometrial protection and prefer a bioidentical progestogen.
• Women in perimenopause using HRT who have had poor tolerability with synthetic progestins (mood changes, libido suppression, bloating with MPA or norethindrone).
• Women who report insomnia as a prominent symptom, since OMP's GABA-A effect can genuinely improve sleep quality, and taking it at bedtime makes the appetite side effect a non-issue.
• Women with endometriosis on estrogen add-back therapy who need endometrial protection and want to minimize androgenic progestogen effects.

Proceed With Extra Care

• Women with PCOS and baseline insulin resistance: carbohydrate cravings on top of existing metabolic vulnerability require active dietary management.
• Women with binge-eating disorder or a history of disordered eating: discuss the appetite-stimulating mechanism explicitly with your prescriber before starting.
• Women with peanut allergy: Prometrium contains peanut oil and is contraindicated. Compounded progesterone in an alternative oil base is required.
• Women who cannot take OMP at bedtime due to scheduling or shift work, as the post-dose appetite window becomes clinically meaningful if you are awake during it.
• Women with diabetes or pre-diabetes: monitor fasting glucose and HbA1c at baseline and within 3-6 months of initiation.

The Evidence Gap: What We Still Do Not Know

Women have been historically underrepresented in metabolic pharmacology trials, and appetite as a primary endpoint in progestogen research is thin. Here is what is extrapolated versus directly studied:

Directly studied in women:

• OMP's endometrial protective efficacy (PEPI Trial, JAMA 1995)
• OMP's lipid profile compared to MPA (PEPI Trial)
• Allopregnanolone's GABA-A receptor activity in human brain tissue
• Luteal-phase appetite and carbohydrate preference in naturally cycling women

Extrapolated from mechanistic or animal data:

• The specific contribution of OMP-derived allopregnanolone to appetite versus other pathways
• Whether the appetite effect persists at 12-24 months (tolerance data in HRT-specific populations is lacking)
• Whether lower doses (50 mg, used in some compounded formulations) produce meaningfully less appetite stimulation

Requesting that your clinician document appetite and weight at each HRT review visit creates the real-world data that research currently lacks.

A Note on Compounded Progesterone Versus Prometrium

Some women are prescribed compounded oral progesterone, either because of peanut allergy, cost, or because their prescriber prefers custom dosing. Compounded progesterone in sesame oil or sunflower oil behaves pharmacokinetically similarly to Prometrium, with comparable allopregnanolone conversion, so the appetite effects described here apply equally.

Compounded products are not FDA-approved and are not subject to the same manufacturing consistency standards. The FDA has noted that batch-to-batch variability in compounded hormones is a real concern. If you are on compounded progesterone and notice erratic appetite changes that do not follow the timing pattern described above, inconsistent absorption from the compounded product may be a factor worth raising with your pharmacist and prescriber.

Quick Reference: OMP Dosing and Appetite Implications

| Dosing Regimen | Dose | Schedule | Appetite Risk | |---|---|---|---| | Continuous (postmenopause) | 100 mg | Nightly at bedtime | Low to moderate | | Sequential (perimenopause or cycling) | 200 mg | Nightly for 12 days/cycle | Moderate to high | | Luteal phase support (fertility) | 200-300 mg | Nightly or split dose | Moderate to high | | Sleep-focused off-label | 100 mg | Nightly at bedtime | Low |

For all regimens, bedtime dosing is preferred both for tolerability (sedation is an asset at night) and for minimizing conscious appetite stimulation.